

Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis

Gabriele Simonini, Claudia Bracaglia, Marco Cattalini, Andrea Taddio, Alice Brambilla, Cinzia De Libero, Denise Pires Marafon, Roberto Caputo, and Rolando Cimaz

ABSTRACT. Objective. To identify clinical predictors of relapse in childhood autoimmune chronic uveitis after stopping systemic treatment.

Methods. A retrospective, multicenter, cohort study.

Results. Ninety-four children in remission, receiving no treatments and with at least a 6-month followup, were enrolled. A higher probability of maintaining remission after discontinuing treatment was shown in idiopathic compared with juvenile idiopathic arthritis uveitis (Mantel-Cox chi-square = 23.21) if inactivity had been obtained within 6 months from starting systemic treatment (Mantel-Cox chi-square = 24.17) and by antitumor necrosis factor- α treatment (Mantel-Cox chi-square = 6.43).

Conclusion. Type of disease, time, and type of systemic therapy to achieve inactivity predict different duration of uveitis remission after treatment withdrawal. (J Rheumatol First Release April 1 2017; doi:10.3899/jrheum.161336)

Key Indexing Terms:

CHILDREN THERAPY WITHDRAWAL AUTOIMMUNE CHRONIC UVEITIS RELAPSE

Because it is a serious and potentially disabling disease, a step-by-step immunosuppression therapy is generally used in childhood autoimmune chronic uveitis (cACU)^{1,2,3}. However, once uveitis inactivity is achieved, there is no guideline advice regarding the exact duration of systemic treatment^{4,5}. Evidence suggests that a longer period of inactivity with treatment reduces the chance of relapse after therapy withdrawal⁶. However, bad disease activity and a worse visual acuity in juvenile idiopathic arthritis (JIA) uveitis are strongly associated with a lower probability of remission^{7,8}. Knowing the natural clinical history of cACU

could be helpful in driving therapeutic decisions for each patient. We aimed to identify potential clinical predictors of relapse in patients with cACU who stopped systemic treatment.

MATERIALS AND METHODS

Study design. Ours was a multicenter, retrospective, comparative cohort study from 4 tertiary pediatric rheumatology centers.

Inclusion criteria. At the time of enrollment, patients were required to fulfill the following: (1) disease onset at ≤ 16 years of age; (2) vision-threatening noninfectious, chronic uveitis that previously obtained remission receiving at least 1 disease-modifying antirheumatic drug (DMARD) or/and any biologic modifier treatment as single therapy or as combined therapy for at least 3 months and thereafter discontinued by decision of the involved physician; (3) inactive uveitis (defined as rare cells or < 1 cell per field at standard slit-lamp examination) for at least 3 months after discontinuation of all treatments, including topical treatment, thus achieving remission according to the Standardization of Uveitis Nomenclature (SUN) working group criteria⁹; (4) outcome measures collected according to the SUN criteria¹⁰; and (5) at least a 6-month period of followup without any treatment.

Outcome measures. Main outcome was, once remission was achieved, the time up to the first relapse after discontinuing any treatment. Additionally, we defined inactivity on therapy if inactive uveitis has been maintained for at least 3 consecutive months after discontinuing any steroid treatment, but still receiving systemic therapy. Secondary outcomes were time to achieve uveitis inactivity on therapy, time to steroid discontinuation, and time of inactivity on therapy. Anterior chamber cells and flare were graded according to the SUN grading schemes criteria. Intraocular inflammation was considered "active" or uncontrolled if the inflammatory activity grade was ≥ 1 at any examination^{9,10}.

Study protocol. Chart review has been performed to extract data at the time of the enrollment, and then every 3 months up to the time of the first flare, and in any case when uveitis flared. Data were collected using a customized uveitis database available online (trial.biostatistica.net) for each center with a unique user name and password entering anonymous data, with the coordinating center (Florence) acting as data manager. Because this study is an

From the Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; Ophthalmology Unit, Anna Meyer Children's Hospital, Florence; Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome; Pediatric Immunology and Rheumatology Unit, Brescia; Institute of Child Health and Maternal Health IRCCS Burlo Garofolo; University of Trieste, Trieste, Italy.

G. Simonini, MD, Associate Professor, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; C. Bracaglia, MD, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS; M. Cattalini, MD, Pediatric Immunology and Rheumatology Unit; A. Taddio, MD, Institute of Child Health and Maternal Health IRCCS Burlo Garofolo, and University of Trieste; A. Brambilla, MD, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; C. De Libero, MD, Ophthalmology Unit, Anna Meyer Children's Hospital; D. Pires Marafon, MD, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS; R. Caputo, MD, Ophthalmology Unit, Anna Meyer Children's Hospital; R. Cimaz, MD, Associate Professor, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence.

Address correspondence to Dr. G. Simonini, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence, Viale Pieraccini 24, 50139 Florence, Italy.

E-mail: gabriele.simonini@unifi.it

Accepted for publication February 21, 2017.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved.

observational, retrospective chart review, ethical committee approval was not required in accordance with the policy of the involved institutes.

Statistical analysis. A priori power analysis, setting effect size (f) at 0.40 and power at 0.95, showed that 86 participants in all groups combined would be required. The Mann-Whitney U test, Kruskal-Wallis test, Wilcoxon signed-rank test for paired samples, chi-square test, and Fisher's exact test, when appropriate, were used to compare data. The following data were considered as variables for correlations, and as covariates for the survival curves: age at the entry study/age at the initiation of systemic therapy, sex, associated JIA and joint activity status (active vs inactive), disease duration, age at uveitis onset, uveitis duration, active uveitis duration, time interval between the uveitis onset and the initiation of systemic therapy, drug therapy administration (dose and frequency), concomitant medications including methotrexate (MTX) when used in association with antitumor necrosis- α (anti-TNF- α), cumulative corticosteroid dose and its duration, previous treatment type and duration, number of previous flares, best corrected visual acuity at the time of enrollment, eye complications because of chronic uveitis (including glaucoma, synechiae, band keratopathy, cystoid macular edema, vitritis, and cataract), time to obtain remission, time of inactivity while receiving therapy, and followup time. Pearson and Spearman correlation tests were used to determine correlation coefficients for different variables. To identify predictors of outcome, Cox regression model and Kaplan-Meier curves were constructed, each at the mean of the above-reported covariates. Analyses were performed on SPSS package for MAC, version 23.0 (SPSS).

RESULTS

From June 2013 to December 2015, of 335 children followed for cACU, 94 (28%, median age 11.6 yrs, range 3.2–15.4) were eligible for our study because they had discontinued all treatments and showed a persistent remission over at least 6 months. Sixty-seven (49 female, 18 male) were affected by JIA: 35 oligoarticular onset, 18 polyarticular, 10 psoriatic arthritis, and 4 enthesitis-related arthritis. Twenty-seven (11 female, 16 male) were affected by idiopathic chronic uveitis (IdCU): 9 intermediate and the remaining by panuveitis. Demographic information and other variables reported into the statistical analysis section did not differ

between JIA and IdCU. Fifty-three children previously received MTX at 15 mg/mq²/week, 36 adalimumab (ADA) at 24 mg/mq²/2 weeks, and 5 infliximab (IFX) at 8 mg/kg, every 6 weeks in combination with MTX 7.5 mg/week. Twenty-eight children also received MTX in combination with anti-TNF- α : 23 with ADA, 5 with IFX (Table 1).

The total median time in remission was 12 months (range 6–59; Figure 1). At last available followup after treatment discontinuation (median 49 mos, range 15–68), 26 out of 87 children (29.9%) maintained a complete remission over a median period of 28 months. Seven children (4 JIA, 3 IdCU) were lost at followup: 3 previously received MTX, 3 IFX, and 1 ADA. At 49 months of followup, which was the longest period common to the 2 groups, 15/24 children with IdCU (62.5%) compared with 11/63 children with JIA (17.4%) were still in remission, while 52/63 JIA-cACU (82.5%) compared with 9/24 IdCU (37.5%) already relapsed at least once during the followup time (Pearson chi-square test-continuity correction = 14.74, $p < 0.0001$). A higher probability of maintaining uveitis remission after discontinuing treatment was shown in IdCU compared with JIA (Mantel-Cox chi-square = 23.21, $p < 0.0001$; Figure 2). Antinuclear antibody positivity was associated with a higher probability of uveitis flare in overall population (Mantel-Cox chi-square = 6.12, $p < 0.01$), but not in subanalysis limited to JIA (Mantel-Cox chi-square = 0.78, $p = 0.37$) and IdCU (Mantel-Cox chi-square = 2.55, $p = 0.11$).

No variable resulted in significant predictors of long-lasting remission without therapy, including sex (Mantel-Cox chi-square = 2.17, $p = 0.21$), visual acuity (Mantel-Cox chi-square = 1.03, $p = 0.21$), type of treatment, DMARD vs anti-TNF- α (Mantel-Cox chi-square = 0.23, $p = 0.62$), concomitant versus nonconcomitant medication

Table 1. Comparison of variables for correlations, and as covariates for the survival curves, in 67 children with JIA-associated uveitis and in 27 with IdCU. Continuous variables are expressed as median (range) values.

Variable	JIA Uveitis, n = 67	IdCU, n = 27	p
Age, yrs	10.8 (3.2–12.3)	13.4 (5.2–15.4)	0.13
Female/male, n	49/18	11/16	0.82
Age at onset of uveitis, yrs	5.4 (2.2–11.4)	7.2 (4.6–11.2)	0.09
Uveitis history duration, mos	31 (12–68)	28 (11–84)	0.73
Time interval between uveitis onset and systemic treatment able to achieve remission, mos	48 (6–75)	40 (12–84)	0.71
Systemic treatment duration, mos	25 (8–51)	20 (9–46)	0.32
MTX, n (%)	41 (61.2)	12 (44.5)	0.21
Infliximab, n (%)	3 (4.5)	2 (7.4)	0.94
Adalimumab, n (%)	23 (34.3)	13 (48.1)	0.31
Concomitant MTX administration, n/no. receiving anti-TNF- α	18/26	10/15	0.6
Time of remission, mos	11 (6–28)	13.1 (6–59)	0.0001
Total time followup, mos	48 (26–68)	50 (15–65)	0.91
No. previous flares before systemic treatment	4 (2–6)	3 (2–7)	0.43
BCVA as LogMAR, at the study entry, mean (\pm SD)	0.24 (0.36)	0.23 (0.32)	0.6
Patients with eye complications due to chronic uveitis, n (%)	11 (16.6)	4 (14.8)	0.84

Significant data are in bold face. JIA: juvenile idiopathic arthritis; IdCU: idiopathic chronic uveitis; BCVA: best corrected visual acuity; MTX: methotrexate; anti-TNF- α : antitumor necrosis factor- α .




Figure 1. Survival curve of the time up to the first uveitis relapse after achieving remission and any therapy withdrawal (time on remission, off therapy) of the 94 children with autoimmune chronic uveitis enrolled.




Figure 2. Survival curve of the time up to the first uveitis relapse after achieving remission and any therapy withdrawal (time in remission, off therapy) in IdCU and in JIA-associated uveitis (Log-rank, Mantel-Cox chi-square = 23.21, $p < 0.0001$). IdCU: idiopathic chronic uveitis; JIA: juvenile idiopathic arthritis.

(Mantel-Cox chi-square = 0.13, $p = 0.83$), time of inactivity over 1 year of treatment (Mantel-Cox chi-square = 2.63, $p = 0.12$), as well as over 2 years of treatment (Mantel-Cox chi-square = 0.05, $p = 0.94$). However, stratifying the overall cohort by the time to achieve inactivity on treatment, the Cox

regression analysis (at mean of the above-reported covariates) showed a higher probability of maintaining remission after treatment discontinuation if remission had been obtained within 6 months from starting systemic treatment (Mantel-Cox chi-square = 24.17, $p < 0.0001$; Figure 3). At




Figure 3. Survival curve of the time up to the first uveitis relapse after achieving remission and any therapy withdrawal (time in remission, off therapy) in childhood autoimmune chronic uveitis who obtained inactivity on therapy within 6 months (≤ 6 mos) and after 6 months (> 6 mos) from starting systemic therapy (Log-rank, Mantel-Cox chi-square = 24.17, $p = 0.0001$).

49 months of followup, 21/48 children who obtained inactivity on therapy within 6 months (43.8%) compared with 5/39 who obtained inactivity on therapy after 6 months (12.8%) were still in remission (Pearson chi-square test-continuity correction = 17.35, $p < 0.0001$).

In children who obtained inactivity on therapy within 6 months, the probability of maintaining remission after treatment discontinuation were significantly higher if they received anti-TNF- α treatment compared with children who received MTX (Mantel-Cox chi-square = 6.43, $p = 0.011$).

DISCUSSION

Even with a retrospective study, our results suggest that JIA and time to achieve inactivity, rather than the length of treatment, can predict different duration of uveitis remission after therapy withdrawal. Achieving inactivity and remission by anti-TNF- α results in a predictor of low chance of relapse once systemic therapy is stopped. If duplicated in a prospective study, these data might be helpful in building up a tailored therapy for a better standard of care.

As previously reported^{11,12,13,14}, we confirm that JIA uveitis shows a persistent chronic course with a risk of relapse after treatment withdrawal that is significantly higher than that of IdCU over time. In agreement with Kalinina Ayuso, *et al*⁶ regarding MTX withdrawal, our data in a larger cohort confirm the majority of cACU relapse over 1 year after stopping treatment. Unfortunately, we were not able to replicate that a longer period of remission on treatment reduces the chance of relapse after stopping therapy.

Conversely, our present study points out that a shorter time to achieve persistent inactivity on treatment represents a significant predictor to keep inactivity once systemic treatment is stopped. In addition, to the best of our knowledge, our cohort represents the longest and largest cohort of cACU reporting natural history after anti-TNF- α and MTX treatment withdrawal. To date, several multicenter studies have attempted to identify predictors of remission in chronic uveitis in adults as well as in children^{15,16,17,18,19}, but data are lacking regarding the optimal duration for systemic treatment and the risk of relapse after therapy withdrawal.

Before drawing firm conclusions, some limitations must be discussed. First, the inherent selection bias of 4 tertiary referral centers must be considered; in addition, children enrolled represent a heterogeneous population with possible variable responses to treatment. However, outcome results were weighted and corrected to include significant clinical variables, such as concomitant medication and visual acuity.

Heterogeneity due to the underlying disease might also affect these results, even if we also reported a subcohort analysis limited to JIA. Further, since different cACU are not included in our cohort, our present data might not represent the effect size of the overall cACU population. However, eligible children derived from the 335 children with cACU, encompassing different types of uveitis (Behçet, early onset sarcoidosis, tubulointerstitial nephritis, and uveitis syndrome) and doubtless JIA and IdCU, represent the most diffuse uveitis types in the pediatric population.

Notably, another shortcoming is the type of assigned

treatment used; it was not randomly assigned, but chosen based on physician decision, current knowledge of systemic treatment in cACU, and drug availability.

However, ours might be a pilot study for a multicenter prospective study aimed to identify, according to JIA or not JIA uveitis, time and type of systemic therapy to achieve inactivity, the more suitable approach to obtain the longest possible remission after therapy withdrawal.

REFERENCES

1. Angeles-Han ST, Rabinovich CE. Uveitis in children. *Curr Opin Rheumatol* 2016;28:544-9.
2. Simonini G, Cimaz R, Jones GT, Macfarlane GJ. Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review. *Semin Arthritis Rheum* 2015;45:238-50.
3. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. *Arthritis Care Res* 2014;66:1073-84.
4. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. *Eur J Ophthalmol* 2007;17:743-8.
5. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology* 2014;121:785-96.e3.
6. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. *Am J Ophthalmol* 2011;151:217-22.
7. Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. *J AAPOS* 2008;12:539-45.
8. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. *Arthritis Rheum* 2007;56:647-57.
9. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005;140:509-16.
10. Jabs DA. Improving the reporting of clinical case series. *Am J Ophthalmol* 2005;139:900-5.
11. Heinz C, Mingels A, Goebel C, Fuchsluger T, Heiligenhaus A. Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course. *J Rheumatol* 2008;35:1403-7.
12. Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. *Ocul Immunol Inflamm* 2013;21:478-85.
13. Artornsombudh P, Pistilli M, Foster CS, Pujari SS, Gangaputra SS, Jabs DA, et al. Factors predictive of remission of new-onset anterior uveitis. *Ophthalmology* 2014;121:778-84.
14. Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. *Ann Rheum Dis* 2005;64:871-4.
15. Chan SM, Gan KD, Weis E. Characteristics and predictors of recurrence of anterior and intermediate uveitis in a Canadian referral centre. *Can J Ophthalmol* 2010;45:144-8.
16. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, et al; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Remission of intermediate uveitis: incidence and predictive factors. *Am J Ophthalmol* 2016;164:110-7.
17. Kalinina Ayuso V, ten Cate HA, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. *Br J Ophthalmol* 2011;95:646-51.
18. Kalinina Ayuso V, Ten Cate HA, van der Does P, Rothova A, de Boer JH. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. *Am J Ophthalmol* 2010;149:994-9.e5.
19. Kalinina Ayuso V, Ten Cate HA, van der Does P, Rothova A, de Boer JH. Male gender and poor visual outcome in uveitis associated with juvenile idiopathic arthritis. *Am J Ophthalmol* 2010; 149:987-93.